S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Forecast, Price & News

$0.60
0.00 (0.00%)
(As of 10/2/2023 ET)
Compare
Today's Range
$0.57
$0.63
50-Day Range
$0.58
$1.35
52-Week Range
$0.56
$5.07
Volume
2.49 million shs
Average Volume
1.66 million shs
Market Capitalization
$106.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.80

Sangamo Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
866.7% Upside
$5.80 Price Target
Short Interest
Healthy
5.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Sangamo Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$3 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.84) to ($0.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

289th out of 975 stocks

Biological Products, Except Diagnostic Industry

43rd out of 156 stocks


SGMO stock logo

About Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Price History

SGMO Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Analyst Ratings for Sangamo Therapeutics
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
A Preview Of Sangamo Therapeutics's Earnings
5 DNA Stocks Billionaires Are Loading Up On
See More Headlines
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Company Calendar

Last Earnings
8/08/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
478
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$5.80
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+866.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-192,280,000.00
Pretax Margin
-93.50%

Debt

Sales & Book Value

Annual Sales
$111.30 million
Book Value
$1.80 per share

Miscellaneous

Free Float
171,799,000
Market Cap
$106.27 million
Optionable
Optionable
Beta
1.20

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Alexander D. Macrae Ch.B (Age 60)
    M.B., MRCP, Ph.D., CEO, Pres & Director
    Comp: $1.17M
  • Ms. Prathyusha Duraibabu CPA (Age 44)
    M.B.A., Sr. VP, CFO & Principal Accounting Officer
    Comp: $628.08k
  • Mr. D. Mark McClung (Age 60)
    Exec. VP & COO
    Comp: $710.3k
  • Dr. Jason D. Fontenot Ph.D. (Age 53)
    Sr. VP & Chief Scientific Officer
    Comp: $682.76k
  • Phillip Ramsey
    Head of Technical Operations
  • Ms. Aron Feingold
    Head of Corp. Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby (Age 48)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Whitney Jones
    Chief People Officer
  • Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 61)
    Sr. VP & Chief Devel. Officer
  • Dr. Lisa Rojkjaer M.D. (Age 57)
    Chief Medical Officer













SGMO Stock - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SGMO shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12-month price objectives for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $10.00. On average, they anticipate the company's stock price to reach $5.80 in the next twelve months. This suggests a possible upside of 866.7% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2023?

Sangamo Therapeutics' stock was trading at $3.14 on January 1st, 2023. Since then, SGMO stock has decreased by 80.9% and is now trading at $0.60.
View the best growth stocks for 2023 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.02. The biopharmaceutical company had revenue of $6.84 million for the quarter, compared to analyst estimates of $22.33 million. Sangamo Therapeutics had a negative net margin of 90.86% and a negative trailing twelve-month return on equity of 50.17%.

What ETFs hold Sangamo Therapeutics' stock?

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $0.60.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $106.27 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

The company employs 478 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -